The Boston-based blood management technology developer posted profits of $48.1 million, or 94¢ per share, on sales of $209.5 million for the three months ended Sept. 26, 2020, for a 28.3% bottom-line gain on a sales decline of -17.1%.
Adjusted to exclude one-time items, earnings per share were 62¢, 11¢ ahead of Wall Street, where analysts were looking for sales of $207.7 million.
“Our business was impacted by COVID-19, which is reflected in our second quarter and first-half results,” Haemonetics CEO Chris Simon said in a news release. “Customer end-market demand remains strong despite the pandemic and we are poised for recovery. We are completing our turnaround, delivering operational excellence and advancing our innovation agenda, including FDA clearance of Persona, to build a foundation for transformational growth.”
Haemonetics’ new, proprietary Persona technology is designed to customize plasma collection based on an individual donor’s body composition.
Haemonetics is not offering financial guidance for the full year 2021 due to uncertainties caused by the COVID-19 pandemic.
HAE shares were down -1% at $101.22 per share in early-morning trading today.